Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Formulation Study of GSK2838232 in Healthy Subjects
NCT02289482Phase 1Terminated
- Sponsor
- GSK
- Start
- Nov 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK2838232 in human immunodeficiency virus infection (HIV) (4 arms), sponsored by GSK. Primary endpoints: Adverse events (AEs) assessments up to 7 weeks, Safety assessed by laboratory evaluations up to 7 weeks and 5 more. Started Nov 2014; status: terminated.
02
Drugs
GSK2838232
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02289482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02289482.